Boston Scientific Corporation (NYSE:BSX) SVP David A. Pierce sold 8,763 shares of the stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $27.74, for a total transaction of $243,085.62. Following the transaction, the senior vice president now owns 24,201 shares in the company, valued at approximately $671,335.74. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of Boston Scientific Corporation (BSX) opened at $27.46 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. The stock has a market cap of $37,710.00, a price-to-earnings ratio of 45.02, a P/E/G ratio of 1.96 and a beta of 0.96. Boston Scientific Corporation has a 1-year low of $23.03 and a 1-year high of $29.93.
Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.31. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. Boston Scientific’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.27 EPS. analysts anticipate that Boston Scientific Corporation will post 1.25 earnings per share for the current year.
Several research analysts have recently commented on BSX shares. BMO Capital Markets restated a “buy” rating and set a $30.00 price target on shares of Boston Scientific in a research note on Friday, October 13th. Needham & Company LLC restated a “buy” rating and set a $32.00 price target on shares of Boston Scientific in a research note on Tuesday, October 3rd. SunTrust Banks restated a “buy” rating and set a $34.00 price target on shares of Boston Scientific in a research note on Monday, October 2nd. Stifel Nicolaus restated a “buy” rating and set a $32.00 price target on shares of Boston Scientific in a research note on Monday, September 25th. Finally, Canaccord Genuity dropped their price target on shares of Boston Scientific from $36.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, November 29th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $31.00.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Boston Scientific Corporation (BSX) SVP Sells 8,763 Shares of Stock” was published by BBNS and is the property of of BBNS. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/insider-selling-boston-scientific-corporation-bsx-svp-sells-8763-shares-of-stock/1827728.html.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with our FREE daily email newsletter.